What Are the Risks of HRT in Breast Cancer Survivors? An evolving understanding of the risks and benefits of HRT has led to a reevaluation of the role of HRT for breast cancer survivors.

Systemic #HRT increases #breastcancer recurrence risk by 80% in HR+ patients (HR 1.8), while HR- patients show no significant increase (HR 1.19). Shared decision-making is essential. 🩺

Read the review: https://bit.ly/3QkAJTS

#BCSM #MedEd #OncTwitter #ClinicalTrials

Research Rewind: Notable Phase 1/2 Breast Cancer Trial Readouts From Quarter 1 of 2026 | OncLive Read our recap of top phase 1 and 2 breast cancer data announcements and highlights that may influence further clinical research and developments.

Miss any early-phase breast cancer data? OncLive has you covered with a look at some of the key phase 1/2 data to emerge in breast oncology during the first 3 months of 2026 #bcsm #oncology www.onclive.com/view/researc...

FDA Flashback: Breast Cancer Decisions and News From March 2026 | OncLive Read a refresh of the top FDA news in breast cancer from March 2026, including anticipated approvals and a biosimilar approval.

Read a refresh of the top @fda.gov news in breast cancer from March 2026, including anticipated approvals and a biosimilar approval. #bcsm #oncology

www.onclive.com/view/fda-fla...

Genetic variants involved in rapid immune response linked to earlier breast cancer onset in BRCA1 carriers Damaging variants in genes involved in a rapid immune response (innate immunity) are significantly linked to earlier breast cancer onset in carriers of the harmful BRCA1 genetic mutation, reveal preli...

Damaging missense variants in innate immunity genes are associated with earlier age of #breastcancer onset in #BRCA1 185delAG carriers.

#hereditarycancer #bcsm #cancerresearch #genetics #womenshealth

Via @medicalxpress.com

Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international coho... The clinical implications of specific pathogenic and likely pathogenic variant (LP/PV) types and locations in the BRCA1 or BRCA2 tumor-suppressor genes remain to be elucidated.

Association between type and location of germline #BRCA pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with #breastcancer: Results from an international cohort study.

#bcsm #hereditarycancer #womenshealth #genetics #cancerresearch

Menopause, Menarche Impact Breast Cancer Risk in BRCA Carriers In a compelling advance for cancer genetics and epidemiology, a groundbreaking study has been published exploring the interplay between natural reproductive milestones and breast cancer risk among

Natural menopause, menarche and #breastcancer risk in #BRCA pathogenic variant carriers: A Mendelian randomization analysis by UK researchers.

#hereditarycancer #bcsm #medsky #womenshealth #genetics

Read our recap of top phase 3 breast cancer data announcements and highlights that may influence clinical practice in the near future! #bcsm #oncology

www.onclive.com/view/researc...

Dr Kalinsky on the Medical Oncologist’s Role Within Integrative Breast Oncology | OncLive Kevin Kalinsky, MD, MS, FASCO, discusses the role of integrative oncology programs and the importance of survivorship clinics within cancer care.

WATCH 👀: @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, discusses the role of integrative oncology programs and the importance of survivorship clinics within cancer care.

See the whole video here 📷: www.onclive.com/view/dr-kali...

#bcsm #oncology

WATCH: @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, discusses the potential role of the SERENA-6 trial data in breast oncology. #bcsm #oncology

See more insights from Dr Kalinsky about a multidisciplinary tumor board on breast cancer management! www.onclive.com/video-series...

Denosumab-Adet Gains FDA Approval for All Indications of Denosumab | OncLive The biosimilar Ponlimsi is approved for all reference denosumab indications, and applications for an omalizumab biosimilar candidate have been accepted.

The biosimilar Ponlimsi is approved for all reference denosumab indications, and applications for an omalizumab biosimilar candidate have been accepted.
#oncology #FDA #medtwitter #prostatecancer #pcsm #bcsm
www.onclive.com/view/denosum...

PHILA: Pyrotinib-Based Dual Anti-HER2 Regimen Extended Survival in Metastatic Breast Cancer - Oncology Nurse Advisor Investigators delivered updated results from the phase 3 PHILA trial evaluating the pyrotinib or placebo plus trastuzumab and docetaxel in patients with untreated HER2+metastatic breast cancer.

Pyrotinib plus trastuzumab and docetaxel outperformed trastuzumab and docetaxel alone as an initial treatment for HER2-positive metastatic #breastcancer. Published in @bmj.com and @cancertherapyadv.bsky.social.

https://bit.ly/47TBedD

#bcsm

Dr Kalinsky on the Role of Tumor Boards in Metastatic Breast Cancer Management | OncLive Kevin Kalinsky, MD, MS, FASCO, notes the advantages of collaborating with multidisciplinary tumor boards when managing metastatic breast cancer.

WATCH: @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, notes the advantages of collaborating with multidisciplinary tumor boards when managing metastatic breast cancer. #MBCC26 #bcsm #oncology
www.onclive.com/view/dr-kali...

The use of taxane-based chemotherapy was associated with an increased risk for #neuropathy and balance issues among #breastcancer survivors who were 65 years or older at the time of therapy. Published in @ascocancer.bsky.social journal JCO Oncology Practice.

https://bit.ly/4t3AQl0

#bcsm

Dr Diab on the Role of the BCI for Optimizing Endocrine Therapy Use in Breast Cancer | OncLive Sami Diab, MD, discusses the use of genomic assays for determining whether extended adjuvant therapy is needed for patients with breast cancer.

WATCH 👀: Sami Diab, MD, discusses the use of genomic assays for determining whether extended adjuvant therapy is needed for patients with breast cancer.

📷 See the whole video here: www.onclive.com/view/dr-diab...

#bcsm #oncology

Want to learn more about the presentations from #MBCC26? #bcsm experts share takeaways and lingering questions from the meeting.

⭐ Sign up to read: www.onclive.com/view/multidi...

@kalinskykevin.bsky.social @winshipcancer.emory.edu @mskcancercenter.bsky.social @fredhutch.org #bcsm #oncology

🎙️The first episode of the Breast Cancer Briefing podcast is LIVE! Sara Nunnery, MD, MSCI, & Kelly E. McCann, MD, PhD, discussed the HER2+ breast cancer treatment paradigm. #bcsm #oncology

WATCH the video podcast on our site, or LISTEN where you get your podcasts ➡️ www.onclive.com/view/t-dxd-t...

Dr Diab on Using the BCI for Recurrence Risk Assessment in HR+ Breast Cancer | OncLive Sami Diab, MD, discusses facets of individualized risk assessment for premenopausal patients with early-stage HR-positive, node-negative breast cancer.

WATCH 👀: Sami Diab, MD, discusses facets of individualized risk assessment for premenopausal patients with early-stage HR-positive, node-negative breast cancer.

📷 See the whole video here: www.onclive.com/view/dr-diab...

#bcsm #oncology

Dr Diab on the Value of the Breast Cancer Index for Assessing Disease Recurrence Risk | OncLive Sami Diab, MD, discusses the value of the Breast Cancer Index for identifying disease recurrence risk in breast cancer after adjuvant endocrine therapy.

WATCH 👀: Sami Diab, MD, discusses the value of the Breast Cancer Index for identifying disease recurrence risk in breast cancer after adjuvant endocrine therapy.

📷 See the whole video here: www.onclive.com/view/dr-diab...

#bcsm #oncology

A pleasure having Professor Steffi Oesterreich @upmchillmancc.bsky.social @upmc.com @mageewomens.bsky.social visit us at @wchospital.bsky.social today and discussing #research collaborations in #lobular #breastcancer #bcsm
@lobularbca.bsky.social

PHILA: Pyrotinib-Based Dual Anti-HER2 Regimen Extended Survival in Metastatic Breast Cancer Investigators delivered updated results from the phase 3 PHILA trial evaluating the pyrotinib or placebo plus trastuzumab and docetaxel in patients with untreated HER2+metastatic breast cancer.

Pyrotinib plus trastuzumab and docetaxel outperformed trastuzumab and docetaxel alone as an initial treatment for HER2-positive metastatic #breastcancer. Published in the @bmj.com.

https://bit.ly/40SqeJJ

#bcsm

WATCH 👀: Marla Lipsyc-Sharf, MD, of @uclahealth.org, discusses the evolution of ctDNA testing in breast cancer management. #bcsm #oncology

📷 Check out the full interview for more breast cancer testing insights from Dr Lipsyc-Sharf! www.onclive.com/shorts/explo...

Dr Lipsyc-Sharf on the Use of the Signatera Genome Assay in Breast Cancer Management | OncLive Marla D. Lipsyc-Sharf, MD, highlights the clinical evolution of the Signatera Genome test for residual disease surveillance in patients with breast cancer.

WATCH 👀: Marla D. Lipsyc-Sharf, MD of @uclahealth.org, highlights the clinical evolution of the Signatera Genome test for residual disease surveillance in patients with breast cancer.

📷 See the whole video here: www.onclive.com/view/dr-lips...

#bcsm #oncology

Dr Diab on the Clinical Relevance of the Breast Cancer Index in HR+ Early-Stage Disease | OncLive Sami Diab, MD, highlights the use of the BCI for guiding adjuvant hormonal therapy decision-making in patients with early-stage, HR-positive breast cancer.

WATCH 👀: Sami Diab, MD, highlights the use of the BCI for guiding adjuvant hormone therapy decisions in early-stage, HR+ breast cancer.

📷 See the whole video here 📷: www.onclive.com/view/dr-diab...

#bcsm #oncology

WATCH: Sami Diab, MD, emphasizes the importance of considering different patient priorities in cancer care.

See our site for more breast cancer management insights! #bcsm #oncology

www.onclive.com/clinical/bre...

Just released a couple of new episodes of my podcast - Never knew I wanted to be a breast cancer survivor #bcsm bcbecky.com/wp-admin

Combination Treatment Benefits Patients With Advanced Breast Cancer That Has Spread to Brain | OncLive Tucatinib and trastuzumab, plus capecitabine, may improve symptoms and extend survival in some breast cancer patients with leptomeningeal metastasis.

A study from @danafarber.bsky.social demonstrated that tucatinib and trastuzumab, plus capecitabine, may improve symptoms and extend survival in some breast cancer patients with leptomeningeal metastasis. #oncology #bcsm
Read more here: www.onclive.com/view/combina...

Have you checked out our newest episode? In our "Report Back from SABCS" Dr. Bora Lim shares some of the notable highlights you need to stay informed & educated with what's new in #MetastaticBreastCancer treatment.
🎧 Listen (all channels) or 🔗 buff.ly/rOQzgg5
#BCSM #CanSky

Online patient materials for #AI in #mammography exceed recommended 6th-grade readability levels. Analysis shows most content requires a college-level education.

Read the review: ➡️ https://bit.ly/4uBkKRf

#BCSM #MedEd #HealthLiteracy

Sacituzumab govitecan–based regimens now hold category 1 preferred regimen recommendations for the first-line treatment of metastatic triple-negative breast cancer in the updated NCCN Guidelines #bcsm #oncology www.onclive.com/view/updated...

Dr. Lim from @utmdanderson.bsky.social discusses targeted therapy, ADC's moving to first line, emerging treatments for TNBC and more.
🎧 Listen (all channels) or 🔗 buff.ly/rOQzgg5
#MBC #SABCS #ClinicalTrials #BCSM #CanSky #podcast